and provide and Thanks us. an business. have joining update share our thank Jody good everyone this our opportunity afternoon pleased you to progress I'm on to for
quality efforts senior the system. department I'd talk past XX hires I we've to engineering resources and quality and effective quality In and our discussing are initiatives with results key a the our improvements. more clinical think Before and the and like months to robust added showing about made
a huge a among quality needed status maintenance, standard system and calibrations equipment was addressing an quality within management our following and As preventive last items with audit focus a initiated group late an project comprised quality I'm of that proud XXX supplier XXX example internal quality completed I'm operating also plan be and completed our the on to year improvement procedures, others. This to the in to the before item last we FDA all announce to with items actions from received the report and XXX expected pleased year end. say have we've to form submitted December September. we the the final we that completed of agency final related
business noticed vascular catheter our procedures. to Turning life variations internal we've current shelf in the our testing during DABRA recently of
additional should we XXXX. As sales a we commercial be catheters information resume The result in shared we FDA paused confirm voluntarily first the stability subsequently in the life this before of the resolved commercial and of which quarter the we DABRA requested September believe of data FDA. to with shelf XXXX shipments
reduced not to important pause clinical shipments is catheters the company. material this not It our ability supply note you to commercial clinical we the of our use trial impact a and impact recall financial the that to is sites have paused does specialists in clinical of the As our indication handful however trial. focusing have efforts atherectomy so on to will our team commercial been for
Now have the on moving made catheters. extend our future as as progress life our with well to engineering efforts development our we fantastic catheters with related efforts to of those initiatives shelf to
talk let's life. First shelf about
limit and our the issues issues involve that introduction of to their the shelf of degradation into the understanding the of can sorry inner two the I'm furthered elements cause calibrate water time not core to over coating. calibrate, have one, catheter's life. catheter's and our We catheters unwanted thus The
passing include more encouraging recent accelerated Our DABRA aging obtained process aging our real-time in accelerated efforts and generation two specification for and changes. both manufactured next data XXX% from even of very from to two-month tests. challenging mitigate were testing both the Recent catheters catheters with most tests sterilization material, lots issues the
we ongoing feasible six longer approaching with testing if believe design. is shelf analysis months life indicates not is our this that Although this
to data will have extend We will shelf months in aging the six longer. life year develop by a remain place end continue our tests that accelerated confident we comprehensive and conclusive or to plan more to
engineering next DABRA with catheter. our shelf efforts on life extending continue advance our generation and addition schedule to to generation In our on the next progress
workshop this design later evaluated to reminder deliverable braided tortuous this kink over a jacket month catheter more during incorporates DABRA vascular and to be catheter first anatomy. the a resistant subsequently the engineering will several of the a one to for in navigating complete for day and the submit expect half catheter when it make clearance. this with FDA will physicians still XXXX As The who hands-on work
in-house compatible complete pleased We ahead the we're also to to the This guidewire experienced to and concept XXXX. during previously I'm catheter quarter by of expected third the the engineering now. early of on design prototypes with is an for made report and firm have outsourced compatible DABRA catheter substantial development guidewire. progress have prototypes evaluation several that We in-vitro available about excited the event be we the standard schedule design designs. allow as project incorporate this expect catheter also We evaluated generation will input XXXX. overall hands-on end to features move the the usability on next it a later forward will us during workshop. as catheters I'm for compatible the to guidewire DABRA still with finalizing on and month our development this before the really performance of
activate and XXXX are sites subjects. opting XX enrolled obtain quarterly subjects. made since COVID-XX study platform subject approved Our an This capacity has their the in postpone as Many the and first atherectomy last studies call starting DABRA February XXX for during the up to indication We the still FDA is clinical XXXX potential in clinical at procedures new subjects well. our significant sites to our pandemic. to additional for pandemic progress reduced some clinical enroll trial March operating substantially impacted are ability and sites to
sites COVID-XX sites. cleared the sites cannot However, and actively the in evaluating to pleased been are pandemic are operating expected of an additional participants the COVID-XX our of subjects the over Since additional potential enrolled forward increase we Currently are to screen five sites enrollment our past are significant and be to at that studies months. two a study completed. three XX to-date. impact have we XX this five for when call study last under have investor will clinical now are on estimate due seen to report a enroll The we unpredictable subjects we subjects have cleared in moving protocols we activity that total enrolled
customers has Pharos of laser. capital by our such many Our acquisition also as the or been equipment impacted purchase dermatology COVID-XX as business delay
offices predominantly dermatology. is recent However, activity a recorded in revenue which the with physician XX% at we growth increase QX in versus product
timing believe continue in opportunity the pandemic. contribution We there to our to revenues future. the potential our influenced the by ability those will and dermatology is grow changes further to the of businesses, dermatology as COVID-XX ongoing grow during as to business an increase well changes cash business strategy be Any the
at to reduced overall forward physician our in our adjust While as with the level well procedures the being as of to performed initiatives initiatives to uncertainty key COVID-XX. we spending we strategic have invest offices going due the continued reduction
year X employees the sales facing today. As legal various cooperate an our reduced as to to navigate I we the to the strategy last and believe force are government of issues Also the with continuing example XX we has company investigations appropriate DABRA us. from employees
over will discuss to results. Andrew I Now call turn to financial Andrew? the our
